about
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphomaPromising treatments of tomorrow for multiple sclerosis.A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine TregsRoles for trafficking and O-linked glycosylation in the turnover of model cell surface proteins.Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications.CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis)Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSPRole of post-translational modifications of HTLV-1 Tax in NF-κB activation.Fingerprinting acute leukemia: DNA methylation profiling of B-acute lymphoblastic leukemia.Salubrinal acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritisEffective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Lymphocyte modulation in a baboon model of immunosenescence.Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro.New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cellsSam68 modulates the promoter specificity of NF-κB and mediates expression of CD25 in activated T cells.Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.The distinct response of gammadelta T cells to the Nod2 agonist muramyl dipeptide.Antibody-based therapy of leukaemia.Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection.Novel immunobiologics for psoriasis.Targeting interleukins to treat severe asthma.The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.Immunological and histochemical analyses of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders.The role of basiliximab in the evolving renal transplantation immunosuppression protocol.Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.Cyclosporine A effectively inhibits graft-versus-host disease during development of Epstein-Barr virus-infected human B cell lymphoma in SCID mouse.Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody
P2860
Q24626963-8A7C8AC6-CBE4-4EBC-870C-8C12491B5B9BQ33670947-6090940F-C0A0-4992-9BB8-9AD4F7540382Q33830604-3838DFCB-848F-4B68-882F-C126DE231F61Q33888529-42A3CB37-77F4-41C5-A27D-B67DA34E8277Q33992622-1D7F6F2E-CB0F-48F1-BBFB-1BF1C9E69397Q34063120-F68B80A5-8E8A-4532-A56D-08F2E8439892Q34077332-58FC2C52-0434-4CBD-A35C-711207693E7BQ34130411-31952D0B-FAEF-436D-AA54-E4E752079F80Q34409257-1A02FC02-62B2-40D7-8248-707C624D4AD0Q34667760-080ACC6B-AB38-41E0-82F8-356B95E3C5C7Q34878458-174C983C-2973-4343-AEFC-60CF110B44E0Q35017525-5AFCAAE5-2E51-40CF-ABCF-45FFCC3C18ABQ35118294-14C1F327-F7AB-423B-B9E0-470DBD2BE2ADQ35849893-ECA35471-D8DA-4870-8335-B35AECF774D1Q35854970-8BC47F47-8372-4E3B-8886-AF5C271AB24CQ35923417-43B45C9D-5E2B-47BF-801F-386047270F97Q36293343-BE698B1F-F973-4DE6-8D24-4C45B9A0B10AQ36695084-BA5E9BD5-8D10-46A9-A0AF-5CABC25F6756Q36748702-D71CC092-C278-4C28-A5E7-37AFB5238BC6Q36832132-CCD571A9-3656-4A23-8706-12AFAB218C31Q36915936-F5D711C2-262C-4343-81A7-B485750D0DB7Q36933399-07D69BF6-58A5-41D9-BB53-F70673226C49Q36956380-8BB9EE35-B977-432E-854D-504977D18A14Q37207538-16F77A89-4E13-4271-9B9E-102CE06BC9BFQ37605247-1E52EBD7-0787-4EB7-A687-D49862A01E7AQ37618059-26239EC0-CADA-4E3B-B78B-5564A5A84470Q37664478-A055B179-5309-4FD5-A6EE-ABB58252CC24Q38042721-A1328A89-A9E4-4A74-8E1B-962A91716AE5Q39044411-974D4538-EC09-432D-AE50-FE6328FA0E0EQ42692619-3A70DA3F-39E9-453B-A17F-1CCE16EEA596Q43078141-27FA26E4-4308-4F23-B902-89D27EDCCA72Q43485988-0BF659B4-5838-4B5A-80FE-CA675D1269C8Q45721862-3878F91F-0A65-4632-9362-5845A839C4E0Q57755478-CAFC7D92-628B-4B42-9970-115E15D73509
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Advances in interleukin 2 receptor targeted treatment
@ast
Advances in interleukin 2 receptor targeted treatment
@en
Advances in interleukin 2 receptor targeted treatment
@nl
type
label
Advances in interleukin 2 receptor targeted treatment
@ast
Advances in interleukin 2 receptor targeted treatment
@en
Advances in interleukin 2 receptor targeted treatment
@nl
prefLabel
Advances in interleukin 2 receptor targeted treatment
@ast
Advances in interleukin 2 receptor targeted treatment
@en
Advances in interleukin 2 receptor targeted treatment
@nl
P2860
P1476
Advances in interleukin 2 receptor targeted treatment
@en
P2093
Waldmann TA
P2860
P304
P356
10.1136/ARD.59.SUPPL_1.I109
P407
P478
59 Suppl 1
P577
2000-11-01T00:00:00Z